| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Copenhagen Muscle Research Centre and 2Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark; 3Skeletal Muscle Research Laboratory, Center for Nutrition Metabolism and Endocrinology, Royal Melbourne Institute of Technology University, Bundoora; 4St. Vincent’s Institute of Medical Research, University of Melbourne, Fitzroy; and 5Commonwealth Scientific and Industrial Organisation Health Sciences and Nutrition, Parkville, Australia
Submitted 15 June 2004 ; accepted in final form 20 August 2004
To determine whether IL-6 increases lipolysis and fat oxidation in patients with type 2 diabetes and/or whether it exerts this effect independently of changes to the hormonal milieu, patients with type 2 diabetes (D) and healthy control subjects (CON) underwent recombinant human (rh)IL-6 infusion for 3 h. Rates of appearance (Ra) and disappearance (Rd) of [U-13C]palmitate and [6,6-2H2]glucose were determined. rhIL-6 infusion increased (P < 0.05) palmitate Ra and Rd in a similar fashion in both groups. Neither plasma glucose concentration nor glucose Ra/Rd was affected by rhIL-6 infusion in either group, whereas rhIL-6 infusion resulted in a reduction (P < 0.05) in circulating insulin in D. Plasma growth hormone (GH) was increased (P < 0.05) by IL-6 in CON, and cortisol increased (P < 0.05) in response to IL-6 in both groups. To determine whether IL-6 was exerting its effect directly or through activation of these hormones, we performed cell culture experiments. Fully differentiated 3T3-L1 adipocytes were treated with PBS (control) IL-6, or IL-6 plus dexamethasone and GH. IL-6 treatment alone increased (P < 0.05) lipolysis, but this effect was reduced by the addition of dexamethasone and GH such that IL-6 plus dexamethasone and GH had blunted (P < 0.05) lipolysis compared with IL-6 alone. To assess whether IL-6 increases fat oxidation, L6 myotubes were treated with PBS (Control), IL-6, or AICAR, a compound known to increase lipid oxidation. Both IL-6 and AICAR markedly increased (P < 0.05) oxidation of [14C]palmitate compared with Control. Acute IL-6 treatment increased fatty acid turnover in D patients as well as healthy CON subjects. Moreover, IL-6 appears to be activating lipolysis independently of elevations in GH and/or cortisol and appears to be a potent catalyst for fat oxidation in muscle cells.
cytokines; metabolism; insulin sensitivity
This article has been cited by other articles:
|
|
 |
|
  B. K. Pedersen Edward F. Adolph Distinguished Lecture: Muscle as an endocrine organ: IL-6 and other myokines J Appl Physiol, October 1, 2009; 107(4): 1006 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Steinberg and B. E. Kemp AMPK in Health and Disease Physiol Rev, July 1, 2009; 89(3): 1025 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Chakravarthy, Y. Zhu, L. Yin, T. Coleman, K. L. Pappan, C. A. Marshall, M. L. McDaniel, and C. F. Semenkovich Inactivation of hypothalamic FAS protects mice from diet-induced obesity and inflammation J. Lipid Res., April 1, 2009; 50(4): 630 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Pedersen and M. A. Febbraio Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6 Physiol Rev, October 1, 2008; 88(4): 1379 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G Holmes, J. L Mesa, B. A Neill, J. Chung, A. L Carey, G. R Steinberg, B. E Kemp, R. J Southgate, G. I Lancaster, C. R Bruce, et al. Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPAR{alpha} and UCP2 expression in rats J. Endocrinol., August 1, 2008; 198(2): 367 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weigert, M. Dufer, P. Simon, E. Debre, H. Runge, K. Brodbeck, H. U. Haring, and E. D. Schleicher Upregulation of IL-6 mRNA by IL-6 in skeletal muscle cells: role of IL-6 mRNA stabilization and Ca2+-dependent mechanisms Am J Physiol Cell Physiol, September 1, 2007; 293(3): C1139 - C1147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Qatanani and M. A. Lazar Mechanisms of obesity-associated insulin resistance: many choices on the menu Genes & Dev., June 15, 2007; 21(12): 1443 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P Corcoran, S. Lamon-Fava, and R. A Fielding Skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise Am. J. Clinical Nutrition, March 1, 2007; 85(3): 662 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Harmancey, J.-M. Senard, P. Rouet, A. Pathak, and F. Smih Adrenomedullin Inhibits Adipogenesis Under Transcriptional Control of Insulin Diabetes, March 1, 2007; 56(3): 553 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Pedersen, M. A. Febbraio, and R. A. Mooney Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis J Appl Physiol, February 1, 2007; 102(2): 814 - 816. [Full Text] [PDF]
|
|
|
|
|
|
A. L. Carey, G. R. Steinberg, S. L. Macaulay, W. G. Thomas, A. G. Holmes, G. Ramm, O. Prelovsek, C. Hohnen-Behrens, M. J. Watt, D. E. James, et al. Interleukin-6 Increases Insulin-Stimulated Glucose Disposal in Humans and Glucose Uptake and Fatty Acid Oxidation In Vitro via AMP-Activated Protein Kinase. Diabetes, October 1, 2006; 55(10): 2688 - 2697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Wernstedt, A. Edgley, A. Berndtsson, J. Faldt, G. Bergstrom, V. Wallenius, and J.-O. Jansson Reduced stress- and cold-induced increase in energy expenditure in interleukin-6-deficient mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R551 - R557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Smith and G. E. O. Muscat Orphan nuclear receptors: therapeutic opportunities in skeletal muscle Am J Physiol Cell Physiol, August 1, 2006; 291(2): C203 - C217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Frost, G. J. Nystrom, and C. H. Lang Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R773 - R784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bruunsgaard Physical activity and modulation of systemic low-level inflammation J. Leukoc. Biol., October 1, 2005; 78(4): 819 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hiscock, C. P. Fischer, M. Sacchetti, G. van Hall, M. A. Febbraio, and B. K. Pedersen Recombinant human interleukin-6 infusion during low-intensity exercise does not enhance whole body lipolysis or fat oxidation in humans Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E2 - E7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Yu and H. N. Ginsberg Adipocyte Signaling and Lipid Homeostasis: Sequelae of Insulin-Resistant Adipose Tissue Circ. Res., May 27, 2005; 96(10): 1042 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. W. Petersen and B. K. Pedersen The anti-inflammatory effect of exercise J Appl Physiol, April 1, 2005; 98(4): 1154 - 1162. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
